Raghu Vikram K, Smith Kenneth J
University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Intest Fail. 2024 Oct-Dec;4. doi: 10.1016/j.intf.2025.100051. Epub 2025 Mar 18.
Cost-effectiveness analysis is a comparative methodology used to determine how costs and benefits align for a given treatment when evaluated against one or more competing strategies. In intestinal failure, this may include direct comparisons between medical treatments vs transplant or individual care decisions. Teduglutide and antimicrobial lock therapy provide two recent examples of treatments in the United States that came under scrutiny due to cost. We demonstrate the use of cost-effectiveness analysis to critically examine these treatments in the US as an example that may be adapted to various healthcare contexts worldwide. We then discuss the required steps to employ this methodology more effectively in pediatric intestinal failure.
成本效益分析是一种比较方法,用于确定在与一种或多种竞争策略进行评估时,给定治疗的成本和效益如何匹配。在肠衰竭中,这可能包括药物治疗与移植之间的直接比较或个体护理决策。替度鲁肽和抗菌封管疗法是美国近期因成本问题而受到审查的两种治疗方法的例子。我们展示了如何使用成本效益分析来严格审查美国的这些治疗方法,作为一个可适用于全球各种医疗环境的例子。然后,我们讨论了在儿科肠衰竭中更有效地应用这种方法所需的步骤。